Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

ALT

  • Home
  • ALT
Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds
Posted inGastroenterology Internal Medicine news

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds

Posted by MedXY By MedXY 06/17/2026
In adults with suspected MASH, 200 IU/day vitamin E lowered ALT as effectively as 400 IU/day and 800 IU/day over 24 weeks, with no short-term safety signal, supporting lower-dose use if vitamin E is chosen.
Read More
Diabetes, Male Sex, and Low HBsAg, HDV RNA, and ALT Predict Spontaneous HDV Suppression in Chronic Hepatitis D
Posted inGastroenterology Infectious Diseases news

Diabetes, Male Sex, and Low HBsAg, HDV RNA, and ALT Predict Spontaneous HDV Suppression in Chronic Hepatitis D

Posted by MedXY By MedXY 05/20/2026
In 1,610 untreated chronic hepatitis D patients, spontaneous HDV suppression was uncommon but increased over time. Diabetes, male sex, and lower baseline HBsAg, HDV RNA, and ALT predicted suppression and fewer liver-related events.
Read More
  • Fistulotomy with Primary Sphincteroplasty for Complex Anal Fistulas: Balancing Cure with Continence Preservation
  • Reevaluating Lumpectomy Margin Thresholds in HR-Positive DCIS: Insights from the NRG Oncology/NSABP B-35 Trial
  • Advancing Microsurgical Reconstruction: Real-world Evaluation of the Symani Surgical System® in the PRIMO Study
  • Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration
  • Evaluating the Impact of a Structured Caesarean Reduction Strategy on Perinatal Outcomes: Insights from a Decade-long Italian Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in